Calcium and Vitamin D3: study protocols
30 study groups took Calcium together with Vitamin D3. These are the doses the studies gave. They are not a recommendation.
Dose per serving from research: Calcium
29 study groups in 15 studies say how much Calcium participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 500 mg to 1 g, 48% of 29 study groups.
| Daily dose | Study groups |
|---|---|
| 250 mg to 500 mg | 5 |
| 500 mg to 1 g | 14 |
| 1 g to 2.5 g | 10 |
Dose per serving from research: Vitamin D3
22 study groups in 12 studies say how much Vitamin D3 participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 100 IU to 250 IU, 36% of 22 study groups.
| Daily dose | Study groups |
|---|---|
| 100 IU to 250 IU | 8 |
| 250 IU to 500 IU | 5 |
| 500 IU to 1,000 IU | 7 |
| 1,000 IU to 2,500 IU | 2 |
Commonly used together
13 of 30 study groups took Calcium and Vitamin D3 with something else, but nothing that 3 or more different studies gave.
30 study groups
| Study | ||||
|---|---|---|---|---|
| Two Randomized Trials of Low-Dose Calcium Supplementation in Pregnancy 2024 · India trial, 500-mg group · Adults aged 18 years or older who were nulliparous and pregnant at less than 20 weeks’ gestation | 500 mg | 250 IU | — | — |
| Evaluation of efficacy of oral calcium phosphate as an adjunct to standard-of-care regular phototherapy in cases of neonatal jaundice: a hospital-based double-blind, randomised, placebo-controlled trial 2024 · intervention group · Neonates with neonatal jaundice requiring phototherapy, including term and preterm infants | 75 mg/kg | 200 IU | — | 40 |
| Two Randomized Trials of Low-Dose Calcium Supplementation in Pregnancy 2024 · India trial, 1500-mg group · Adults aged 18 years or older who were nulliparous and pregnant at less than 20 weeks’ gestation | 1.5 g | 250 IU | — | — |
| Acupuncture in Treating Osteopenia: A Multicenter, Randomized, Controlled Clinical Trial 2024 · acupuncture group · Patients with osteoporosis; age and sex not reported | 600 mg | — | 26 weeks | 116 |
| Acupuncture in Treating Osteopenia: A Multicenter, Randomized, Controlled Clinical Trial 2024 · control group · Patients with osteoporosis; age and sex not reported | 600 mg | — | 26 weeks | 110 |
| The Effect of the Modified Eighth Section of Eight-Section Brocade on Osteoporosis in Postmenopausal Women: A Prospective Randomized Trial 2015 · Ca alone · Postmenopausal women aged 50–75 with inadequate bone mass or osteoporosis | 1.5 g | 600 IU | 1 year | 50 |
| The Effect of the Modified Eighth Section of Eight-Section Brocade on Osteoporosis in Postmenopausal Women: A Prospective Randomized Trial 2015 · MESE + Ca · Postmenopausal women aged 50–75 with inadequate bone mass or osteoporosis | 1.5 g | 600 IU | 1 year | 50 |
| Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis 2018 · PTH group · Postmenopausal women aged 45–80 with osteoporosis | 1.25 g | 200 IU | 48 weeks | 43 |
| Effect of two forms of alendronate administration upon bone mass after two years of treatment 2002 · Group I · Women with postmenopausal osteoporosis | 1.2 g | 800 IU | 2 years | 40 |
| Effect of two forms of alendronate administration upon bone mass after two years of treatment 2002 · Group II · Women with postmenopausal osteoporosis | 1.2 g | 800 IU | 2 years | 40 |
| Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis 2018 · Alendronate (ALN) group · Postmenopausal women aged 45–80 with osteoporosis | 1.25 g | 200 IU | 48 weeks | 22 |
| The joint effect of energy reduction with calcium supplementation on the risk factors of type 2 diabetes in the overweight population: a two-year randomized controlled trial 2021 · energy-reduction with calcium supplementation group (ER-CSG) · Overweight adults aged 20–70 with low dietary calcium intake and no major disease; received dietary energy-reduction education as well as supplements | 400 mg | — | 2 years | 300 |
| The joint effect of energy reduction with calcium supplementation on the risk factors of type 2 diabetes in the overweight population: a two-year randomized controlled trial 2021 · calcium supplementation group (CSG) · Overweight adults aged 20–70 with low dietary calcium intake and no major disease | 400 mg | — | 2 years | 298 |
| The effect of empagliflozin (sodium-glucose cotransporter-2 inhibitor) on osteoporosis and glycemic parameters in patients with type 2 diabetes: a quasi-experimental study 2024 · Intervention group · Adults aged 58–71 with type 2 diabetes and osteoporosis | 600 mg | — | 26 weeks | 50 |
| The effect of empagliflozin (sodium-glucose cotransporter-2 inhibitor) on osteoporosis and glycemic parameters in patients with type 2 diabetes: a quasi-experimental study 2024 · Control group · Adults aged 59–72 with type 2 diabetes and osteoporosis | 600 mg | — | 26 weeks | 49 |
| One year B-vitamins increases serum and whole blood folate forms and lowers plasma homocysteine in older Germans 2015 · Vitamin D3 plus calcium carbonate · Older German adults, mean age 67 years | 456 mg | 1,200 IU | 1 year | — |
| One year B-vitamins increases serum and whole blood folate forms and lowers plasma homocysteine in older Germans 2015 · B-vitamin supplementation · Older German adults, mean age 67 years | 456 mg | 1,200 IU | 1 year | — |
| Plasma levels of adrenaline, noradrenaline, dopamine, serotonin, and cortisol in sarcopenia: comparison with non-sarcopenic individuals and the impact of resistance exercise and nutrition interventions 2025 · Combined exercise and nutritional intervention (sarcopenic participants; early versus delayed intervention trial) · Adults older than 65 years with sarcopenia | 600 mg | 800 IU | 12 weeks | 57 |
| Potassium citrate supplementation results in sustained improvement in calcium balance in older men and women 2013 · potassium citrate 60 mmol/day · Healthy men and women older than 55 years, with 24-hour urine calcium at or above the study threshold; women were more than five years past menopause. | 630 mg | — | 26 weeks | 17 |
| Potassium citrate supplementation results in sustained improvement in calcium balance in older men and women 2013 · potassium citrate 90 mmol/day · Healthy men and women older than 55 years, with 24-hour urine calcium at or above the study threshold; women were more than five years past menopause. | 630 mg | — | 26 weeks | 17 |
| Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease 2013 · Calcium carbonate · Men and women aged 35 years or older with stage 3–4 chronic kidney disease, GFR <45 mL/min, and serum PTH at least the mid-normal range; all analyzed participants were overweight and had hypertension | 1.5 g | 400 IU | 3 weeks | 8 |
| Potassium Bicarbonate Supplementation Lowers Bone Turnover and Calcium Excretion in Older Men and Women: A Randomized Dose-Finding Trial 2015 · Low-dose KHCO3 group · Healthy ambulatory men and postmenopausal women aged 60 years and older | 600 mg | 500 IU | 12 weeks | — |
| Potassium Bicarbonate Supplementation Lowers Bone Turnover and Calcium Excretion in Older Men and Women: A Randomized Dose-Finding Trial 2015 · High-dose KHCO3 group · Healthy ambulatory men and postmenopausal women aged 60 years and older | 600 mg | 500 IU | 12 weeks | — |
| Enhanced serum levels of tumor necrosis factor-α, interleukin-1β, and -6 in sarcopenia: alleviation through exercise and nutrition intervention 2023 · Early intervention group · Adults aged 65 years and older with sarcopenia | 600 mg | 800 IU | 12 weeks | — |
| Enhanced serum levels of tumor necrosis factor-α, interleukin-1β, and -6 in sarcopenia: alleviation through exercise and nutrition intervention 2023 · Delayed intervention group · Adults aged 65 years and older with sarcopenia | 600 mg | 800 IU | 12 weeks | — |
| Activation of the calcium sensing receptor stimulates gastrin and gastric acid secretion in healthy participants 2009 · cinacalcet group · Healthy men and postmenopausal women aged 45–70 years | 1.2 g | 400 IU | 11 days | 9 |
| Activation of the calcium sensing receptor stimulates gastrin and gastric acid secretion in healthy participants 2009 · placebo group · Healthy men and postmenopausal women aged 45–70 years | 1.2 g | 400 IU | 11 days | 8 |
| Osteocalcin carboxylation is not associated with body weight or percent fat changes during weight loss in post-menopausal women 2015 · Caloric restriction-only group (CR) · Sedentary post-menopausal women aged 50–70 years with overweight or obesity (BMI 25–40 kg/m²) | 1 g | 200 IU | 20 weeks | — |
| Osteocalcin carboxylation is not associated with body weight or percent fat changes during weight loss in post-menopausal women 2015 · Moderate-intensity exercise group · Sedentary post-menopausal women aged 50–70 years with overweight or obesity (BMI 25–40 kg/m²) | 1 g | 200 IU | 20 weeks | — |
| Osteocalcin carboxylation is not associated with body weight or percent fat changes during weight loss in post-menopausal women 2015 · Vigorous-intensity exercise group · Sedentary post-menopausal women aged 50–70 years with overweight or obesity (BMI 25–40 kg/m²) | 1 g | 200 IU | 20 weeks | — |